美国 · 平台与数据 · Yahoo Finance

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

来源：Yahoo Finance · 美国 9 小时前

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential…

在 Yahoo Finance 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finance.yahoo.com)

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

推荐阅读

2 Quantum Computing Stocks That Could Help Make You a Fortune

Audi defends decision to stand by Trump on $4 billion US factory in Georgia

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Vanguard flags a hidden AI risk in your value fund

AI Tokens Post A Mixed Bag As Grayscale Spotlights Three Projects Beyond TAO, NEAR And WLD

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

分享

推荐阅读

2 Quantum Computing Stocks That Could Help Make You a Fortune

Audi defends decision to stand by Trump on $4 billion US factory in Georgia

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Vanguard flags a hidden AI risk in your value fund

AI Tokens Post A Mixed Bag As Grayscale Spotlights Three Projects Beyond TAO, NEAR And WLD